1. Introduction {#s1}
===============

Aortic stenosis is the most common valvular heart disease in the elderly, and a considerable increase in its incidence is foreseen for the coming decades because of the progressive aging of western populations.[@b1],[@b2] Importantly, symptomatic aortic stenosis is not only associated with breathlessness, angina and syncope, but also with a high rate of death, if left untreated.[@b3]--[@b5]

Several studies reported sex-related incidence of complications and death after TAVI, but their results are inconsistent.[@b6]--[@b10] In 2015, Conrotto and his colleges published a meta-analysis, in which they analyzed six studies with 6645 patients from a MEDLINE search, Cochrane Library and Scopus databases and found that female gender was significantly related to a lower risk of death with an odds ratio of 0.82 at one year, but no Mortality difference at 30 day post TAVI.[@b9] A previous meta-analysis from China that involved 27 articles with a total of 9118 patients, concluded that male gender was associated with significantly higher risk for death at both 30 days with a relative risk of 1.37 and at one year with a relative risk of 1.30.[@b8] This was in contrast to the retrospective analysis published by the UK National Institute for Cardiovascular Outcomes Research that investigated 1627 patients from the UK TAVI registry and found no gender-related mortality difference at 30 day and one year follow up.[@b10]

In view of considerable discrepancies with regard to gender-related differences in complications and outcomes after TAVI and the fact that the contributing factors remain incompletely understood; we designed this retrospective observational study to explore the prognostic influence of gender in patients who underwent TAVI in our registry.

2. Methods {#s2}
==========

2.1. Setting {#s2a}
------------

The study is a retrospective observational analysis of a prospectively designed cohort (546 consecutive patients treated at the University Hospital Zurich who were enrolled in Swiss TAVI Cohort from May 2008 to April 2014). The Study took place in University Heart Centre at University Hospital Zurich, Switzerland.

2.2. Study population {#s2b}
---------------------

All patients have been selected for TAVI after multidisciplinary team review by a dedicated heart team of invasive and non-invasive cardiologists, cardiac surgeons and anesthesiologists at our institution. Voluntary informed written consent was obtained from all patients to be included in the Swiss TAVI registry.

2.3. TAVI procedure {#s2c}
-------------------

TAVI was performed via either the transfemoral, transapical or transaortic routes with implantation of diverse valves such as the Medtronic\'s CoreValve^®^, Edwards^®^, Symetis^®^ or Ventor Embracer^®^. A transfemoral first policy was applied, if non-applicable due to any reason (i.e., femoral artery size, aortic disease among others) then alternate access routes were considered.

All procedures conducted through transapical and transaortic routes were performed under general anesthesia, whereas devices implanted through the transfemoral route were most commonly performed with sedation with local anesthesia and only rarely under general anesthesia.

Transthoracic echocardiography was used to measure aortic valve pressure gradient and aortic valve area before TAVI. Aortic regurgitation grade and left ventricular ejection fraction (LVEF) before and after TAVI was also determined in each patient using echocardiography. Mean aortic gradient was further confirmed during cardiac catheterization with invasive measurement before and after the procedure. The Valve Academic Research Consortium Criteria were used to assess and evaluate procedural success, safety end points and clinical outcomes.[@b11]

2.4. Eligibility {#s2d}
----------------

Inclusion criteria were elderly patients with symptomatic severe aortic stenosis, deemed at high risk for conventional surgical aortic valve replacement. Exclusion criteria were patient\'s refusal of informed consent to participate in the registry or lack of capacity to consent and/or high probability of non-adherence to follow-up requirements.

2.5. Outcomes {#s2e}
-------------

The primary outcome comprised all-cause death at 30 days and one year. The secondary outcomes were complications at 30 days after TAVI including stroke, major bleeding, major vascular access related complications, deranged creatinine level, and valve related dysfunction; other studied outcomes were the occurrence of any of the following during the one year follow-up: valve related dysfunction, NYHA III or IV, hospitalization for valve related symptoms and the requirement for a pacemaker implantation. All clinical end points were in concordance with the widely accepted VARC-2 definitions.

2.6. Statistical analysis {#s2f}
-------------------------

Descriptive statistics were performed using summary statistics (mean, standard deviation, and range) for quantitative variables and frequencies for binary and nominal variables. Demographic and clinical variables were tested at baseline against the primary variable of interest (gender) using parametric *t* test, non-parametric chi-square test, or non-parametric Wilcoxon rank sum test as appropriate. Box-and-whisker plots were used to display such relationships. We evaluated the unadjusted effect for gender on survival following TAVI procedure, and then moved on to include the potential clinical and demographic covariates utilizing the log-likelihood and behaviour of the residuals to assess the model fit and confirm the independent impact of gender on survival posy-TAVI. Kaplan-Meier plots were used to display the cumulative survival functions of males and females in terms of the prognostic outcomes specified.

We used the statistical software package SPSS-20 for windows to perform the statistical analysis and for producing graphs and plots. The statistical significance threshold was set at 5%.

3. Results {#s3}
==========

3.1. Baseline and procedural characteristics {#s3a}
--------------------------------------------

Male and female participants of the study were comparable in numbers (49.5 % *vs*. 51.5%). With regard to age, females tended to be significantly older than males (mean: 83.3 ± 6.95 *vs*. 80.7 ± 6.91 years, *P* \< 0.001), while males outnumbered females in terms of the following co-morbidities: diabetes mellitus (59.8% *vs*. 40.2%, *P* = 0.004 ), cardiovascular disease (CAD; 58.7% *vs*. 41.3%, *P* \< 0.001), chronic obstructive airway disease (COPD; 65.0% *vs*. 35.0%, *P* = 0.0003), renal impairment (mean: 130.48 ± 72 *vs*. 100.95 ± 71 µmol/L, *P* \< 0.001) and the need for regular dialysis (76.2% *vs*. 23.8%, *P* = 0.018). On the other hand, there were far less hypertensive males than females \[46.4% *vs*. 53.6%, respectively (*P* \< 0.001)\].

In terms of pre-procedural left ventricular ejection fraction (LVEF), the mean value averaged 55% (SD = 13.3%, range: 19%--88%), with males tending to have significantly lower LVEF than females (51.5% ± 13.9% *vs*. 58.4% ± 11.7%, *P* \< 0.001). These differences in baseline characteristics were reflected in a significantly higher logistic EuroSCORE of males 22.7% ± 14%) compared to females (21.1% ± 12.7%; *P* = 0.031).

The common femoral artery was the most common access site in 85.2% of the cases. In terms of valve types, both the CoreValve^®^ (50.5%) and Edwards^®^ Valve (48.4%), were most commonlly used, while only a few patients received the Symetis^®^ or Ventor^®^ device (1.2% of the cases). With respect to gender differences, more CoreValve^®^ and Symetis^®^ were used in females, whereas more Edwards Sapien^®^ were used in males, a difference that reached statistically significance (*P* = 0.003).

The complete list of baseline characteristics of the patients is depicted in [Table 1](#jgc-15-06-394-t01){ref-type="table"}.

###### Baseline characteristics and procedural demographics.

  Variable                                        All patients          Males             Females               *P* Value
  -------------------------------------------- ------------------ ------------------ ------------------ --------------------------
  Age, yrs                                          82 ± 7.6         80.7 ± 6.91        83.3 ± 6.95              \< 0.001
  BMI, kg/m^2^                                     26.4 ± 4.6        26.4 ± 4.34        26.3 ± 4.86               0.685
  Diabetes mellitus                               132 (24.2%)         79 (59.8%)         53 (40.2%)               0.004
  Dyslipidemia                                    207 (37.9%)        103 (49.8%)        104 (50.2%)                0.72
  Systemic hypertension                           403 (37.9%)        187 (46.4%)        216 (53.6%)              \< 0.001
  Coronary artery disease                         298 (83.8%)        175 (58.7%)        123 (41.3%)              \< 0.001
  Cerebrovascular accidents                       103 (18.9%)         56 (54.4%)         47 (45.6%)               0.228
  Aortic Valvuloplasty                             20 (3.7%)           10 (50%)           10 (50%)                  1
  Dialysis                                         21 (3.8%)          16 (76.2%)         5 (23.8%)                0.018
  Peripheral vascular disease                     110 (20.2%)         63 (61.2%)         47 (45.6%)               0.052
  COPD                                            103 (18.9%)         67 (65.0%)         36 (35.0%)              \< 0.001
  Creatinine, µmol/L                                115 ± 72         130.48 ± 72        100.95 ± 71              \< 0.001
  B-type natriuretic peptide, pg/mL                   4903               5860               4004         0.23 (Log trans = 0.156)
  Hemoglobin, mean g/L                                98.4              101.9               95.1                  0.0883
  LVEF                                            55% ± 13.3%       51.5% ± 13.9%      58.4% ± 11.7%             \< 0.001
  Logistic EuroSCORE                             21.4% ± 15.1%       22.7% ± 14%       21.1% ± 12.7%              0.031
  EuroSCORE II                                    7.3% ± 6.1%        7.8% ± 6.9%        6.9% ± 5.2%               0.151
  STS score, mean                                     6.6                7.1                6.1                   0.0533
  Access (*n*, femoral, apical, aortic)           (461, 79, 1)       (237, 38, 1)       (224, 41, 0)              0.587
  Device (CorValve, Sapien, Symetis, Ventor)    (273, 262, 3, 3)   (121, 155, 0, 2)   (152, 107, 3, 1)          \< 0.0039

Data are presented as mean ± SD or *n* (%) unless other indicated. BMI: body mass index; COPD: chronic obstructive airway disease; LVEF: left ventricular ejection fraction.

3.2. Primary outcome {#s3b}
--------------------

### 3.2.1. 30-day mortality {#s3b1}

In terms of the 30-day all-cause mortality, death occurred in 6.6% of patients (*n* = 37), which was not statistically different between females (7.5%; *n* = 21) and males (6.0%; *n* = 16) (*X*^2^ = 0.2467, df = 1, *P* = 0.6194)

### 3.2.2. 1-year mortality after TAVI {#s3b2}

In terms of the 1-year all-cause mortality following TAVI, the overall mortality rate was 15.0% (*n* = 82), 11.7% (*n* = 33) females *vs*. 18.4% (*n* = 49) males. Applying the Cox regression hazards model, females were more likely to survive \> 1 year following TAVI procedure than males (HR = 1.436, *P* = 0.037); [Figures 1](#jgc-15-06-394-g001){ref-type="fig"} & [2](#jgc-15-06-394-g002){ref-type="fig"}.

![One year mortality outcome after transcatheter aortic valve implantation.](jgc-15-06-394-g001){#jgc-15-06-394-g001}

![Cumulative survival after TAVI.\
TAVI: transcatheter aortic valve implantation.](jgc-15-06-394-g002){#jgc-15-06-394-g002}

Even after adjusting for the effect of all other covariates, the effect of gender on the risk of post-TAVI mortality was statistically significant (adjusted HR = 1.71, *P* = 0.015). So, in patients with comparable covariates, a male patient, will have an increased risk of death after a TAVI than a female patient by 71.0% (95% CI: 11.0%--163.6%).

3.3. Secondary outcomes {#s3c}
-----------------------

Males tended to have higher creatinine plasma levels post-TAVI compared to females (148 ± 101 *vs*. 109.7 ± 98 mg/dL, *P* \< 0.001; [Figure 3](#jgc-15-06-394-g003){ref-type="fig"}).

![Highest creatinine after transcatheter aortic valve implantation.](jgc-15-06-394-g003){#jgc-15-06-394-g003}

Regarding the other possible gender-related differences in outcomes 30 days after TAVI, all were statistically non-significant during short term follow-up (i.e., major bleeding, vascular complications, stroke, valve dysfunction and follow-up NT brain natriuretic plasma level during hospitalization post TAVI) as well as the differences in long-term outcomes during the entire period of follow-up post TAVI (i.e., all causes of valve dysfunction, NYHA III or IV, hospitalization for valve related symptoms or pacemaker implantation) were also not statistically significant. The complete list of the primary and secondary outcomes is depicted in [Table 2](#jgc-15-06-394-t02){ref-type="table"}.

###### Clinical outcomes after TAVI.

  Variable                                All patients      Males       Females     *P* value
  -------------------------------------- -------------- ------------- ------------ -----------
  One-year all-cause mortality              82 (15%)     49 (18.4%)    33 (11.7%)     0.037
  30-day all cause ortality                37 (6.8%)      16 (6.0%)    21 (7.5%)      0.619
  30-day stroke                            21 (3.8%)      13 (4.9%)     8 (2.8%)      0.062
  30-day vascular complications            23 (4.2%)      7 (2.6%)     16 (5.6%)      0.118
  30-day major bleeding                    13 (2.4%)      8 (3.0%)      5 (1.8%)      0.447
  30-day valve dysfunction                  9 (1.6%)      6 (2.2%)      3 (1.1%)      0.447
  Highest creatinine after TAVI           128.4 ± 100    148.0 ± 101   109.7 ± 98   \< 0.001
  BNP after TAVI, pg/mL                       6523          7430          5646       0.4012
  All strokes after TAVI                   29 (5.3%)      18 (6.8%)    11 (3.9%)      0.13
  NYHA class III or IV after TAVI          55 (11.1%)    28 (10.5%)    27 (9.6%)       0.8
  Hospitalization after TAVI               51 (9.3%)     29 (10.9%)    22 (7.8%)      0.291
  Valve related dysfunction after TAVI    163 (42.6%)    75 (28.3%)    88 (31.3%)     0.499
  Pacemaker Implantation                  103 (18.9%)    59 (22.2%)    44 (15.6%)    0.06254

Data are presented as mean ± SD or *n* (%) unless other indicated. TAVI: transcatheter aortic valve implantation.

4. Discussion {#s4}
=============

The current study shows a significant survival benefit of females undergoing TAVI when compared to male patients with severe and symptomatic aortic stenosis. This benefit, although not obvious at 30 days, was significant at one year follow-up with an odds ratio of 1.70. Our finding therefore support the findings of the Italian meta-analysis of 6 studies incorporating 6645 patients, where they found that female gender was significantly related to a lower risk of death at one year, but not at 30 day post TAVI.[@b9]

There is currently no clear cut explanation for the fact that women do better than men after TAVI. However, the interplay of several risk factors and co-morbidities as well as different gender-related cardiac pathophysiological responses to pressure afterload might be involved. Indeed, gender has a major impact on the development of left ventricular hypertrophy due to a different response to pressure overload.[@b12]--[@b15] Indeed, women with aortic stenosis tend to develop a more concentric form of left ventricular hypertrophy with smaller ventricular diameters, greater relative wall thicknesses, and a better systolic function, while men with comparable degree of pressure overload exhibit a more eccentric form of left ventricular hypertrophy with more ventricular dilation, fibrosis, a decreased ejection fraction and development of heart failure.[@b12],[@b16] In line with this interpretation, males of our cohort were found to have statistically significant lower left ventricular hypertrophy at the time of TAVI compared to females (51.5% *vs*. 58.4%). This finding could as well be explained by the fact that more aggressive cardiac remodeling is normally seen in men secondary to longstanding pressure overload; eventually leading to a more dilated left ventricle and less favorable geometry to preserve systolic function.[@b17],[@b18]

At the cellular level, there is a large body of evidence linking such an abnormal myocardial hypertrophy and fibrosis in men with aortic stenosis to increased expression of transforming growth factor beta-1 protein (TGF-β1) and phosphorylation of SMAD2. Furthermore, periostin, a down-stream target of TGF-β1 signaling and a key regulator of cardiac fibrosis is more expressed in men.[@b19] In human failing hearts, up-regulation of periostin expression is associated with cardiac fibrosis.[@b20] Higher periostin levels were finally found in blood obtained from male compared with female patients with heart failure. This link between pattern of remodeling and survival raises the question of optimizing the management of aortic stenosis in a sex-specific manner.[@b21]--[@b23]

From a metabolic point of view, recent findings linking aortic stenosis to common atherosclerotic pathways could help to further explain the lower incidence of coronary artery disease in females in conjunction to the protective role of estrogen with its anti-atheromatous effects, aiding to better area of viable myocardium reflected by a higher left ventricular ejection fraction and swift recovery post TAVI in females.[@b24],[@b25] The latter finding of higher left ventricular ejection fraction and lower percentage of coronary artery disease in women undergoing TAVI compared to men was documented in our study as well as in many other studies like the UK TAVI registry and other Meta-analyses.[@b8]--[@b10]

It is also worth noting that males in our cohort were evidently a sicker population than females, as they had an overall higher surgical risk reflected by a slightly higher Logistic EuroSCORE, along with a higher incidence of comorbidities and cardiovascular risk factors including but not limited to diabetes mellitus, coronary artery disease and renal impairement, in some even requiring hemodialysis. Of note, males tend to have significantly higher creatinine post-TAVI than females. However, this was also true for baseline pre-procedural creatinine levels. Furthermore, in logistic regression analysis we found that an increase in eGFR by one unit makes a patient, on average, less likely to die within 30-days post TAVI (OR = --0.003, 95% CI: --0.005 to --0.001). This impact of renal function has long been addressed in patients undergoing surgical valve replacement, where chronic kidney disease and acute kidney injury after the procedure were both found to be independent predictors of mortality.[@b26]--[@b28] However, these variables created a bit of controversy regarding their predictive ability in TAVI, While some studies have found a staged classification of chronic kidney disease before valve implantation to be a predictor of both mortality and the development of acute kidney injury, others did not share the same view. Furthermore, the association of acute kidney injury with worse outcome is also still debatable due to similar inconsistencies in studies\' outcomes and that the definition of acute kidney injury post TAVI has been much disputed.[@b29],[@b30] Overall, the risk profile of the current cohort of TAVI patients is consistent with most of other registries\' baseline characteristics.[@b8]--[@b10]

Interestingly, the study showed that there were no statistically significant gender differences in the rate of vascular and bleeding complications during the TAVI procedure, although many of the previous studies reported more access-related vascular and bleeding complications in women.[@b31]--[@b33] This may reflect insufficient statistical power, because of the small event numbers off these complications in our study population (4.2% and 2.4%, respectively), but also may reflect the experience of the center and the successful implementation of vascular closure devices to achieve hemostasis post TAVI.

4.1. Limitations {#s4a}
----------------

The current study is limited by being a retrospective analysis, albeit from a prospectively acquired data set. However, the principle comparison is being made between genders (which are fixed) and thus there is less risk of erroneous conclusions from allocation bias. Also, despite that a great care was taken in selecting patients, the possibility of selection bias reflected by Sex-differences in baseline characteristics and comorbidities cannot be completely ruled out, as Men at baseline outnumbered females in term of diabetes mellitus, CAD, COPD, dialysis, lower LVEF, higher logistic EuroSCORE while females were older with higher percentage of Arterial HTN diagnosis, but it is always infeasible to balance and standardize the pre-procedural characteristics giving the fact that TAVI is reserved for elderly patients with severe AS, deemed high risk for conventional surgical intervention and this category of elderly patients likely to present with numerous comorbidities.

4.2. Conclusion {#s4b}
---------------

Female gender is associated with a better survival at one-year follow up after TAVI. This finding reflects that gender plays a significant prognostic role and should be integrated in a potential risk stratification model of patients considered for the procedure. On the other hand, risk factors could be rendered obsolete, as they do not fit the risk profile of a gender based risk assessment. Furthermore, our findings could open the door for a gender tailored medical therapy where males with severe aortic stenosis could benefit from a more intense pre-procedural treatment reflected as an improvement in survival post valve implantation.
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